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Mechanism of intermediate ﬁlament recognition
by plakin repeat domains revealed by envoplakin
targeting of vimentin
Claudia Fogl1,*, Fiyaz Mohammed2,*, Caezar Al-Jassar1,*,w, Mark Jeeves1, Timothy J. Knowles1,
Penelope Rodriguez-Zamora3, Scott A. White4, Elena Odintsova5, Michael Overduin1,w & Martyn Chidgey1
Plakin proteins form critical connections between cell junctions and the cytoskeleton; their
disruption within epithelial and cardiac muscle cells cause skin-blistering diseases and
cardiomyopathies. Envoplakin has a single plakin repeat domain (PRD) which recognizes
intermediate ﬁlaments through an unresolved mechanism. Herein we report the crystal
structure of envoplakin’s complete PRD fold, revealing binding determinants within its
electropositive binding groove. Four of its ﬁve internal repeats recognize negatively charged
patches within vimentin via ﬁve basic determinants that are identiﬁed by nuclear magnetic
resonance spectroscopy. Mutations of the Lys1901 or Arg1914 binding determinants
delocalize heterodimeric envoplakin from intracellular vimentin and keratin ﬁlaments in
cultured cells. Recognition of vimentin is abolished when its residues Asp112 or Asp119 are
mutated. The latter slot intermediate ﬁlament rods into basic PRD domain grooves through
electrosteric complementarity in a widely applicable mechanism. Together this reveals how
plakin family members form dynamic linkages with cytoskeletal frameworks.
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T
he corniﬁed envelope is an essential component of the
epidermal permeability barrier of vertebrate organisms.
Once assembled under the plasma membrane of keratino-
cytes in the outer epidermis it prevents ﬂuid loss from the body.
The plakin protein envoplakin is upregulated during keratinocyte
terminal differentiation, and interacts with the closely related
protein periplakin to initiate corniﬁed envelope formation1. Both
proteins associate with desmosomes, the interdesmosomal plasma
membrane and intermediate ﬁlament cytoskeleton. Together they
represent a paradigm for how plakin proteins assemble onto
intermediate ﬁlaments to create strong yet dynamic cytoskeletal
anchoring for cell adhesion complexes. Other plakin
proteins include the desmosomal protein desmoplakin, the
hemidesmosomal proteins plectin and bullous pemphigoid
antigen 1 (BPAG1, also known as dystonin), microtubule-actin
cross-linking factor 1 (MACF1) and epiplakin2. Although their
architectures have diverged, all plakin proteins except periplakin
contain at least one plakin repeat domain (PRD), which
constitutes a conserved node that links cell junctions directly
to cytoskeletal frameworks, disruption of which has dire
physiological consequences.
Envoplakin and periplakin are targeted by autoantibodies
in the mucocutaneous skin-blistering disease paraneoplastic
pemphigus, which accompanies malignant and benign neoplasia2.
The majority of these patients express antibodies against
envoplakin or periplakin C-terminal sites3. Such antibodies
cause dissociation of cultured keratinocytes by an obscure
mechanism that involves disruption of cell–cell adhesion4.
Other plakin proteins also play vital roles in maintaining
epidermal integrity. Plectin and BPAG1 are essential
components of hemidesmosomes, and mutations in either
protein cause the skin-blistering disease epidermolysis bullosa
simplex2. Mutations in desmoplakin compromise the integrity of
the skin and heart, and can lead to arrhythmogenic right
ventricular cardiomyopathy, a common cause of cardiac arrest
and sudden death in competitive athletes2,5. No mechanism-
based therapies for these disorders are available, and only a few of
the molecular impacts of mutations and antibodies have been
explored6. Thus plakin proteins represent crucial elements for
epidermal and cardiac muscle integrity, and understanding how
they work could inform multiple clinical diagnostic and
intervention strategies.
Plakin proteins engage intermediate ﬁlaments through PRD
domains. Although their respective mechanisms are undeﬁned,
three subclasses of PRD modules have been identiﬁed as types A,
B and C7. Desmoplakin contains one of each of the three PRD
module types, which could each offer different functional
specializations7. Of all the plakin proteins, envoplakin is the
only member to contain a single PRD module, which is connected
to a central coiled coil region through a linker domain (Fig. 1).
The coil dimerizes with periplakin to form a stiff rod that
connects to the hinged plakin domain, and thus to the
membrane8.
As envoplakin is unique in possessing only one PRD module,
we supposed that its singular PRD could incorporate all of the
critical features needed to form strong links to intermediate
ﬁlaments. Moreover, as its partner periplakin lacks any PRD
module, envoplakin’s PRD could tether the entire heterodimeric
complex to the cytoskeleton9. While apo-structures of the PRD-B
and -C domains of desmoplakin have been solved10, the
structural basis of complex formation and speciﬁc cytoskeletal
tethering has yet to be experimentally determined. To establish
how PRDs recognize intermediate ﬁlaments we solved the
envoplakin PRD structure by X-ray crystallography and small
angle X-ray scattering (SAXS). The structure reveals a basic
groove that can accommodate acidic patches on the cylindrical
surface of monomeric or multimeric intermediate ﬁlament
proteins. Complementary interacting residues within the groove
and on vimentin’s rod are revealed by point mutations and
nuclear magnetic resonance (NMR) spectroscopy. Residues
within the groove are shown to be important for targeting
envoplakin to vimentin and keratin networks in cells. The pattern
of conservation of key determinants across the plakin family
infers a universal mechanism for plakin protein binding to the
intermediate ﬁlament cytoskeleton in epithelia, cardiac and
skeletal muscle.
Results
Structure of the envoplakin PRD. To elucidate the mechanism
of intermediate ﬁlament recognition, we determined the complete
structure of envoplakin’s PRD module (Fig. 2a; Table 1). The
construct boundaries were selected based on sequence alignment
(Supplementary Fig. 1a), and the resulting structure was solved to
1.6 Å resolution by single-wavelength anomalous dispersion. The
asymmetric unit was comprised of two PRD molecules designated
‘a’ and ‘b’. Models comprising residues Asp1822 to Ala2014 were
built and reﬁned to R and Rfree factors of 16.8% and 20.5%,
respectively. The electron density was unambiguous for the entire
polypeptide chain, resolving previously undeﬁned features. The
protein was exclusively monomeric as judged by sedimentation
equilibrium experiments at 21, 44 and 65 mM, respectively
(Supplementary Fig. 2a), and sedimentation velocity experiments
at 46 mM. SAXS studies also indicated a single, monomeric state
with an oblong shape (Supplementary Fig. 2b,c). The two
envoplakin PRD molecules in the asymmetric unit are similar,
superimposing with a root mean square (r.m.s.) deviation of 1.1 Å
for 183 aligned Ca atoms. The deviations mainly originate from
lattice contacts. As they are similar both molecules a and b ﬁt
equally well into the SAXS envelope (Supplementary Fig. 2c).
Therefore, molecule a (hereafter referred to as the envoplakin
PRD) was used for subsequent analyses.
Distinctive structural features of envoplakin’s PRD. The
envoplakin PRD structure has two lobes and contains 4.5 copies
of the canonical 38 amino-acid plakin repeat (PR) motif followed
by a C-terminal hairpin turn (Fig. 2a). Each motif is comprised of
an 11 residue b-hairpin followed by an antiparallel pair of a
helices. The overall fold of the envoplakin PRD is most similar to
the structures of the isolated desmoplakin PRD-B (PDB: 1LM7)
and PRD-C (PDB: ILM5) constructs that were resolved
previously at 3.0 and 1.8 Å, respectively10. Most similar was
desmoplakin PRD-C, with which envoplakin exhibits a backbone
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118 841 849 1,542 1,673 1,822 2,014 2,033
215 861 870 1,645 1,756
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Figure 1 | Domain architecture of plakin family members. Envoplakin
contains an N-terminal plakin domain, a central rod domain that forms a
helical coiled coil, and a C-terminal tail region consisting of a linker domain
(LD) and a single plakin repeat domain (PRD). Periplakin lacks a PRD
module whereas desmoplakin possesses three. The domain boundaries are
indicated.
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r.m.s. deviation of 1.6 Å for 186 aligned Ca atoms. All the PRD
structures are congruent, with the irregular PR2 and PR4 helical
features being most divergent structurally. All cases present two
lobes comprised of the closely packed PR1-PR2 and PR3-PR4
motif pairings, respectively, suggesting that the PRD domain may
have originally emerged from duplication of tandem PR
motifs. The core interactions and loop features revealed in
envoplakin’s PRD structure appear to be conserved throughout
envoplakin’s evolution inferring functional importance. Structural
heterogeneity is found in between PR3 and PR4, and involves the
pinning of their b-hairpins into place (Fig. 2b–e). In desmoplakin
PRD-B and PRD-C, these elements are predominantly stabilized
by ion-pair interactions formed by an Asp residue projecting
from the S1 strand (PR position 4) and a positively charged
residue protruding from the H1 helix (PR position 19).
Envoplakin’s b-hairpins differ, despite the fact that their PR
elements (except for PR4) possess the relevant charges at these
positions. This is exempliﬁed in PR3 where Asp1908 and Lys1923
are orientated away from each other, their missing ion-pair
interaction being offset by a hydrogen bond between Asp1908
and Trp1925 (Fig. 2d). Indeed, this arrangement and the presence
of nearby lattice contacts may contribute to the resolution of
envoplakin’s PR3 b-hairpin (Supplementary Fig. 3a–c). In
contrast, the corresponding b-hairpin of desmoplakin PRD-C
(Glu2699 to Lys2705 in chain A, and Lys2702 to Lys2704 in chain
B) appears disordered presumably due to a combination of
a loss of ionic interaction resulting from a non-conservative
substitution at PR positions 4 (Gly2700) and 19 (Glu2715) and an
absence of lattice contacts here10. The lack of deﬁned b-hairpin
structure in PR3 of desmoplakin PRD-C has consequences for the
anti-parallel arrangement of the H1 and H2 helices, which are
closely paired rather than splayed as in envoplakin. A novel
conformation is found in envoplakin’s PR4 motif, where a long
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Figure 2 | Distinguishing features of the envoplakin PRD structure. (a) Ribbon representation of the envoplakin PRD. Plakin repeats 1–5 are coloured
red, green, blue, yellow and purple, respectively, with their PR motifs and secondary structural elements labelled. The N and C termini are labelled and
shown in teal. The arrow indicates the kink of H2 in PR2. (b) Overlay of PR3 from envoplakin (magenta) and desmoplakin PRDs B (olive) and C (grey).
(c) Overlay of PR4 from envoplakin and desmoplakin PRDs B and C. (d) Stabilization of the envoplakin PR3 by hydrogen bonding (black-dashed lines).
(e) Stabilization of PR4 by hydrogen bonding.
Table 1 | Data processing and reﬁnement statistics for the
envoplakin PRD.
Parameters Envoplakin–PRD Envoplakin–PRDi
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (Å) 42.4, 68.8, 112.2 42.3, 68.5, 113.7
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å) 20–1.6 (1.7–1.6) 20–2.2 (2.3–2.2)
Rsym or Rmerge 5.8 (38.5) 10.6 (37.9)
I/sI 27.9 (2.1) 32 (10.9)
Completeness (%) 92.9 (67.2) 99.8 (99.9)
Redundancy 6.9 (2.1) 23.9 (23.5)
Reﬁnement
Resolution (Å) 19.9–1.6
No. reﬂections 41,953
Rwork/Rfree 16.8/20.5
No. atoms
Protein 2,979
Ligand/ion —
Water 441
B-factors (Å2)
Protein 11.1
Ligand/ion —
Water 26.3
R.m.s. deviations
Bond lengths (Å) 0.006
Bond angles () 1.038
PRD, plakin repeat domain.
Values in parentheses apply to data in the highest resolution shell. For both data sets Friedel’s
pairs are treated as independent reﬂections. Native and iodine derivative X-ray data were
collected from single crystals.
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loop is found instead of the canonical b-hairpin. The lack of
regular secondary structure here may be inﬂuenced by Lys2753 in
desmoplakin PRD-C being replaced by Ser1961 in the
corresponding position of envoplakin, which hence cannot
form the salt-bridge interaction that ﬁxes the canonical
b-hairpin in place. However, a compensatory interaction
between Asp1946 and Arg1949 in PR4 may contribute to the
irregular structure of this envoplakin region (Fig. 2e). Finally, the
envoplakin PRD exhibits a 310 helix in PR4 from which Glu1975
protrudes to contact the PR3 and PR5 helices, whereas the
corresponding desmoplakin region adopts no regular secondary
structure. That this element is highly conserved in envoplakin
orthologs but diverges widely between the PRD superfamily
members (Supplementary Fig. 1a,b) suggests a key role here in
relative PR positioning within the domain.
A striking feature observed in envoplakin is the non-canonical
helical structure and distinctive kink of H2 in PR2 (Fig. 2a;
Supplementary Fig. 3d). Its signiﬁcance can now be inferred by
contrasting this feature with the corresponding desmoplakin
elements, as it consistently acts as a junction between segments
that pack within and between PR motifs, respectively. The
deviation from regular a-helical character here appears to be
generated by two distinct mechanisms. In desmoplakin PRD-C,
Pro2690 is responsible for distorting the regular geometry
midway through the helix. Notably, such proline-induced kinks
are hallmarks of transmembrane helices that require ﬂexibility
for movement between the signalling states11. In contrast, the
corresponding positions of the envoplakin PRD and desmoplakin
PRD-B modules are occupied by Asn1898 and Ser2331,
respectively. This reveals that a proline residue is not strictly
required here for kinking, as a shift in hydrogen-bonding pattern
between the donors and acceptors is consistently found in the H2
bend. Moreover, in all PRDs this helical distortion is maintained
by favourable side-chain interactions mediated by residues
comparable to envoplakin Gln1900, Ala1902, Phe1903, Val1879,
Gln1938 and Gly1866. That this kink architecture has been so
well conserved between PRD family members despite the
sequence variability here suggests that the PR2 helical bend
makes a critical contribution, as is supported by neighbouring
functional residues (see below).
Whether ﬂexibility could contribute to the differences between
envoplakin and desmoplakin was assessed by examination of
disorder. The envoplakin PRD domain was uniformly 13C and
15N labelled, its backbone resonances assigned and the order
parameters (S2) estimated using Talosþ (ref. 12). This revealed a
uniformly ordered domain with elevated disorder in the
N-terminal, PR2, PR3 and PR5 b-hairpin loop sequences
(Supplementary Fig. 4a,b). Further disorder was apparent in the
PR2 helices, H1 of PR4, and the H2 and 310 helix of PR4. The
ﬂexibility of the N-terminal end, and the loops of PR3 and PR5, is
further supported by comparatively large r.m.s. deviations
between the two envoplakin molecules which comprise the
asymmetric unit of the crystal structure, and extend to the
desmoplakin PR2 and PR3 hairpin loops, and position of the 310
helix based on consistently high B-factors (Supplementary
Fig. 4c,d). Together this maps out cross-validated dynamic
elements that encircle a major groove, as would be consistent with
a large binding site. Underneath the relatively dynamic surface
formed by PR2, PR3 and PR4 elements is the PRD core which is
stabilized by a single continuous network of buried hydrophobic
contacts that integrates all PR motifs. The alignment reveals that
envoplakin’s core residues are highly conserved across the PRD
family, with divergences in structural and dynamic elements
suggesting specialized functional features (Supplementary Fig. 1).
Vimentin recognition determinants within the PRD. The
electrostatic potential of the envoplakin PRD surface reveals a
polarized protein with a highly positively charged groove
(Fig. 3a). One basic ﬂank is formed by H2 of PR1 and H2 of PR2,
another by S1, S2 and H2 of PR3, while the elongated loop of PR4
forms a cap (Fig. 3a). This surface area contains a deep groove
which is B23Å long and 10Å wide (Fig. 3a). The charge within
its concavity is pronounced. Basic residues protruding from PR2
include Arg1876 in S2, and Arg1895 and Lys1901, which ﬂank
the kink in H2. Additional charges are contributed by Arg1914 in
PR3:S2, Arg1952 in the extended PR4 loop, and Lys1994 from
PR5:H1. The groove is delineated by Arg1952 and Lys1994 at one
end, and Lys1901 and Arg1914 at the other extremity, while
Arg1876 and Arg1895 lie centrally (Fig. 3b). Together this deﬁnes
a major groove that could conceivably accommodate a large
molecular cylinder. Its basic residues are conserved in desmo-
plakin PRD-C but less so in PRD-B10, and while its dimensions
more closely resemble desmoplakin PRD-C, envoplakin’s groove
is slightly narrower albeit similar in length. Interestingly, the
envoplakin PRD’s lattice contacts involving PR3 overlap the large
groove and could conceivably stabilize a conformation relevant to
ligand binding. As no speciﬁc binding determinants have yet been
established and co-crystals proved elusive, we sought to
characterize the interactions by NMR.
Titrations were ﬁrst carried out with full-length human
vimentin protein (vimentinFL) in the absence of salt because
vimentin forms ﬁlaments of heterogeneous lengths that are not
suitable for characterization by NMR in the presence of salt13.
In the absence of salt, vimentinFL forms functional tetramers14.
The optimized solution conditions used here allowed the
a b
PR5
PR2
PR3
PR4
PR1
R1952
R1914
K1901
R1895
R1876
K1994
Envoplakin PRD Envoplakin PRD
C
N
Figure 3 | The envoplakin PRD contains a conserved basic groove. (a) Electrostatic surface potential of envoplakin PRD calculated with DelPhi.
The potential scale ranges from  7 (red) to þ 7 (blue) in units of kT/e. (b) Ribbon representation of the envoplakin PRD highlighting the position of
positively charged residues mutated in this study. The orientation is the same as in a, and the colours as in Fig. 2.
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progressive changes in resolved amide signals to be monitored as
functionally relevant vimentinFL tetramers were added stepwise
into a 15N-labelled envoplakin PRD sample to respective molar
ratios of 0.1:1, 0.5:1, 1:1 and 2:1. The interaction with the
ﬁlaments exhibited slow exchange on the NMR timescale as
evidenced by progressive line broadening. The effect on line
shape was dramatic, with only 18% of the PRD amide peaks
retaining at least 20% of their starting peak intensities at a half
equimolar ligand concentration, with the remainder being around
the detection limit (Supplementary Fig. 5a,b). Together this
suggests that monomeric PRD modules directly assemble on
vimentinFL to form large, stable and slowly tumbling complexes,
and may collectively decorate multiple sites on the ﬁlament.
To examine the roles of basic determinants in binding
vimentinFL, several envoplakin PRD mutants were designed.
These included alanine and charge reversal substitutions of the six
arginine and lysine residues in the groove as well as control
mutations of distal conserved basic residues. The similarity of the
1H,15N resolved spectra of the mutant and wild-type forms
indicated that the proteins were folded (Supplementary Fig. 5a,c).
Only the R1876E and R1952E variants yielded poor peak
dispersion in heteronuclear single quantum coherence spectra,
hence the functional contributions of these positions were
inferred from the corresponding alanine substitutions, which
did not compromise folding.
Binding to vimentinFL was compromised by the R1895E,
K1901E, R1914E, R1952A and K1994E substitutions (Fig. 4a;
Supplementary Fig. 5c,d). Control mutations K1988E and R1990E
had no such deleterious effect on vimentinFL interactions, while
another control mutation, K1847E, decreased envoplakin PRD
binding to vimentinFL to a small extent (Fig. 4a). Overall, the data
are consistent with vimentinFL binding via the positively charged
groove, and indicates the obligate involvement of each of these
residues in tight binding of intermediate ﬁlaments. On the basis
of the dramatic reductions in peak intensity, the R1895E, K1901E,
R1914E, R1952A and K1994E positions play critical roles,
consistent with the high conservation of their positive charges
(Supplementary Fig. 1). The position of the critical Lys1901
residue in the highly conserved helical PR2 kink suggests a pivotal
role in binding. The Arg1914 residue is found in a part of PR3
that displays dramatically different conformers in the different
PRD structures and therefore may help in the induced ﬁt of
ligands. This groove region generally exhibits elevated disorder
(Supplementary Fig. 4) suggesting a ﬂexible character that
could aid in binding. Together this deﬁnes the PRD function
as providing speciﬁc determinants to form the bridges to
intermediate ﬁlament sites for the cell adhesion machinery.
To exclude the possibility that non-speciﬁc electrostatic
association was responsible for envoplakin PRD–vimentin
interactions, a truncated vimentin construct was designed that,
unlike vimentinFL, does not polymerize in the presence of
physiological salt concentrations. This vimentinROD construct
consists of residues 99–249 and encompasses coils 1A and 1B of
the central rod domain. It is a stable monomer as evidenced by
Analytical ultracentrifugation (AUC) in the presence of 150mM
NaCl (Supplementary Fig. 6a), and contains an estimated
a-helical content of 68% based on analysis of its far-ultra
violet circular dichroism spectrum using the CDSSTR algorithm
and reference data set 7 on the DICHROWEB server15,16
(Supplementary Fig. 6b–d). Binding experiments with the
vimentinROD construct were performed by surface plasmon
resonance (SPR) with a BIAcore 3000 instrument in the presence
of 150mM NaCl (Fig. 4b). A binding constant of 19.1 mM was
obtained for wild-type envoplakin PRD binding to the
vimentinROD protein. Interactions of the K1901E and K1914E
mutants were much weaker (69.3 and 132.5 mM, respectively),
while the binding afﬁnity of two control envoplakin PRD mutants
K1847E and K2002E was comparable to wild-type (26.5 and
14.5 mM, respectively). Similar results were obtained with our
NMR binding assay (Supplementary Fig. 5e,f). Overall, the SPR
and NMR binding data validate the predominantly electrostatic
binding mode of the envoplakin PRD for its vimentin ligand,
whether presented as a stable tetramer in low salt or in a
monomeric form in physiological salt.
Determining envoplakin’s intracellular distribution. To estab-
lish the biological role of the basic binding groove, we tested the
effects of envoplakin mutations on co-localization with inter-
mediate ﬁlaments in cultured HeLa cells. Two mutations, K1901E
and R1914E, were selected as residues 1,901 and 1,914 are
exposed but on opposite sides of the binding groove. Neither
K1901 nor R1914 plays a signiﬁcant structural role and both
positions are highly conserved in envoplakins (Supplementary
Fig. 1b). The K1847E and K2002E mutations were chosen as
controls due to their exposed positions outside the binding
groove. When expressed alone the envoplakin C-terminal con-
struct mainly exhibits a punctate cytoplasmic distribution, as
expected from previous studies9, whereas it shows extensive co-
localization with vimentin when co-expressed with a matching
periplakin construct with which it pairs (Fig. 5a; Supplementary
Fig. 7a). In contrast, when envoplakin K1901E and R1914E
mutants were co-expressed with periplakin they only partially co-
localized with vimentin, the majority being cytosolic and diffuse
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Figure 4 | Mutating residues in envoplakin’s basic groove abolishes
vimentin binding. (a) Histogram showing the percentage of 1H,15N amide
peaks retaining more than 20% of their peak intensity on addition of 50mM
full-length vimentin to wild-type (WT) and mutant envoplakin PRD proteins
(100mM) in the absence of salt. (b) SPR analysis of wild-type and mutant
envoplakin PRD binding to vimentinROD in the presence of 150mM NaCl.
The ﬁgures in parentheses are KD values. The data shown is representative
of a number of experiments. KD values were estimated to be:
WT¼ 19.1±1.3mM, K1847E¼ 26.5±2.0 mM, K1901E¼ 69.3±10.6mM,
R1914E¼ 132.5±34.7mM and K2002E¼ 14.5±0.4mM.
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(Fig. 5a). Mutants K1847E and K2002E showed identical patterns
of staining to wild-type envoplakin (Supplementary Fig. 7b),
conﬁrming that the effect was speciﬁc for residues located in the
groove. The intracellular distribution of periplakin was
unaffected, displaying co-localization with vimentin when
expressed with wild-type, K1901E or R1914E mutant
envoplakins (Supplementary Fig. 7c). All four envoplakin
mutants showed similar levels of expression to wild-type
envoplakin, and all four mutants bound periplakin in pull-
down assays (Supplementary Fig. 7d). The co-localization of wild-
type envoplakin with keratin intermediate ﬁlaments was
extensive, whereas that of the K1901E and R1914E mutant
envoplakins was more diffuse (Fig. 5b). Altogether this indicates
that the K1901E and R1914E mutations compromise envoplakin’s
ability to co-localize with intermediate ﬁlaments, establishing the
PRD groove as being responsible for cytoskeletal contact by
cytosolic plakin protein assemblies.
Structural model of the envoplakin PRD–vimentin complex.
Vimentin forms rod-shaped multimeric structures which offer
multiple acidic patches (Supplementary Fig. 8) that could be
recognized by the basic PRD groove. The assemblies were
modelled using High Ambiguity Driven DOCKing (HADDOCK)
for experimentally restrained protein–protein docking17. The
envoplakin residues shown here to be involved in vimentin
binding including Arg1895, Lys1901, Arg1914, Arg1952 and
Lys1994 were used to restrain docking to conserved negatively
charged surfaces within the vimentin rod domain.
The resulting models converged, despite starting with different
vimentin structures including both monomeric and dimeric
states. Vimentin consistently slotted into the positively charged
groove identiﬁed in the envoplakin PRD with minimal structural
rearrangement. The major point of divergence was the angle of
vimentin entry and egress from the groove (Fig. 6a), as expected
given the multiple available vimentin binding surfaces that could
be satisfactorily oriented within broad groove. While several of
vimentin’s acidic patches mediated favourable interactions, the
model with the lowest energy consisted of the PRD contacting
vimentin’s helical Asn102-Leu138 sequence (Fig. 6a;
Supplementary Table 1). The model suggests that direct
interactions are mediated by residues Lys104, Asn111, Asp112,
Asp119 and Lys120 in chain A and Glu106, Arg113 and Glu125
in chain B of the coiled coil dimer (PDB code 3G1E)18. Strikingly,
in all models examined, Lys1901 and Arg1914, which line the
bottom of the groove, appear to form contacts with conserved
vimentin residues. In contrast, Arg1895, Arg1952 and Lys1994
played peripheral roles within the interface, consistent with the
intermediate effects of their mutations as seen by NMR.
Additional PRD groove residues which were proximal to
vimentin include Glu1875, Lys1881, Arg1885 and Lys1948,
which are only moderately conserved. As such, these positions
could help generate speciﬁc complementarity of PRD variants for
diverse intermediate ﬁlament ligands. The overall compatibility of
the binding model infers a shared cytoskeletal recognition
mechanism in which acidic ﬁlament ridges ﬁt into basic PRD
grooves offered by plakin protein assemblies.
To validate the proposed mode of vimentin recognition,
mutant versions of the vimentinROD construct were designed.
This longer construct was required as the envoplakin PRD
showed no detectable binding to a peptide consisting of vimentin
residues 102–138 (equivalent to PDB 3G1E) by SPR in the
presence of salt, presumably because of its inability to form a
stably folded helical coiled coil. The afﬁnity of wild-type
envoplakin PRD for wild-type envoplakinROD was 19.1 mM,
while its afﬁnity for vimentinROD point mutants D112K and
D119K was compromised (105.7 and 48.4 mM, respectively) and
for a double mutant D112K/D119K was effectively abolished
(KD¼ 1.5mM) (Fig. 6b). Hence vimentin’s D112 and D119
residues appear to be crucial for recognition by the PRD.
Nonetheless, other secondary sites cannot necessarily be excluded
and are in fact likely based on the occurrence of similar motifs in
intermediate ﬁlament structures, and the need for adaptive plakin
protein engagement with the cytoskeleton.
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Wider implications for the PRD superfamily. Comparison of
the structural and functional motifs across all 29 human PRD
sequences clariﬁes the functional architecture and reveals a novel
type of subclass module in addition to the established PRD-A, -B
and -C domains. A fourth major subtype is present only in
BPAG1e, plectin and epiplakin. Their ‘PRD-D’ modules are
distinguished by divergent PR4–PR5 sequences that cap their
grooves, and may have weaker intermediate ﬁlament afﬁnities
based on the lower basic character of their grooves (Fig. 7). In
contrast essentially all PRD-C modules offer highly electro-
positive grooves that connect to the structurally independent
linker domains. The PRD-A modules have few or no basic
residues in their grooves, and may offer as of yet undiscovered
functions. The PRD-B subgroup members contain moderately
basic grooves, and lack the PR3 clamp feature found in PRD-C
modules. Together this suggests that plakin proteins represent a
structurally conserved family of cytolinkers that are adapted
through functionally divergent PRD modules to assemble and
dissemble the many ﬁlamentous networks responsible for
maintaining the dynamic integrity of cellular architectures.
Discussion
The corniﬁed envelope presents vertebrate organisms with a
remarkably durable yet adaptable layer of cross-linked protein
that is formed in the outer epidermis and is vital for epidermal
permeability barrier function. Key components include envopla-
kin which, together with the closely related protein periplakin,
form a complex scaffold on which other proteins of the corniﬁed
envelope can be deposited19. Envoplakin is not just expressed in
the epidermis, but is found in a variety of other epithelial tissues
including those of mammary gland, bladder and stomach20, and
this, together with its association with desmosomes at the cell
periphery, strongly suggests that it has a role in intercellular
adhesion with its PRD acting as a molecular linchpin connecting
the membrane directly to the cytoskeleton.
The envoplakin PRD has ﬁve PR motifs, four of which project
basic residues into a long groove, acting as digits that grasp
negatively charged patches on vimentin ﬁlaments. PR3 projects
an apparently dynamic b hairpin with a putative hinge formed by
the absolutely conserved Gly1904 and Gly1918 residues. This
conceivably allows clamping down on a bound ﬁlament by
Arg1914 to lock a ﬁlament into position. Although structurally
inconsequential, charge reversal mutations here disrupt
interactions with vimentin in protein binding and cellular assays.
The PRD groove presents a concave swathe of six basic residues
that are required for binding tightly to vimentin, accommodating
its cylindrical acidic surface. Mutation of single basic binding
determinants reduces but does not completely abolish the ligand
interaction, indicating that polarized curvature with a charged
array is needed for ﬁlament attraction, although non-polar
residues also contribute10. PRD domains from other plakin
proteins contain different numbers of basic determinants, and
given that intermediate ﬁlaments offer multiple potential binding
sites with varying numbers of charged residues, a spectrum of
weak to strong PRD binding to ligands may also be available.
Further complexity is likely to be caused by variations in steric ﬁt
and non-polar contributions from the variety of available
ﬁlaments and potential binding partners as well as 180 reverse
orientations. Altogether this implies that PRD modules are
presented with a wealth of opportunities for sliding and locking
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onto ﬁlaments, facilitating the dynamic assembly and disassembly
of junctional complexes between epithelial cell architectures.
The determinants of plakin protein tethering to the
cytoskeleton appear to be widely held. The major properties of
envoplakin’s long vimentin binding groove are conserved, with
broadly similar diameters, lengths and charge distributions being
presented by the envoplakin and desmoplakin PRD structures.
The envoplakin PRD has ﬂexible loop regions and structural
elements surrounding the positively charged groove. This
includes dynamic elements including the loop region of PR2,
which is situated before R1876, H2 of PR2 which contains K1901,
the loop region of PR3 which lies before K1914 and the H2-310
helical region of PR4 which is situated behind the groove. These
elements could guide ligand entry into the groove. The groove
itself is capable of readily accommodating vimentin ﬁlaments,
which have diameters of 6.7–23.6Å and present multiple acidic
patches on their cylindrical surfaces. Such polyacidic motifs are
conserved in other intermediate ﬁlaments such as desmin, and
keratins 1 and 10. This infers that plakin superfamily proteins
could interact with various ﬁlament partners through a common
binding mode in which a basic groove inducibly accommodates
cylindrical ligands through complementary electrostatic interactions.
Although the envoplakin PRD is clearly capable of binding
intermediate ﬁlaments, it appears that periplakin is largely
responsible for targeting envoplakin–periplakin heterodimers to
the cytoskeleton, consistent with earlier studies9. Thus, when
transfected into cultured cells truncated envoplakin is distributed
in a punctuate pattern throughout the cytoplasm but on
co-expression with truncated periplakin it shows extensive
cytoskeletal co-localization. Intriguingly, when truncated
envoplakin containing R1914E and K1901E mutations is co-
transfected with truncated periplakin, the mutant envoplakins
show only partial co-localization with vimentin whereas
periplakin retains its original staining pattern. Given that the
truncated mutant envoplakin and truncated periplakin proteins
interact, then how can the different distributions of the proteins
be reconciled? We suggest that periplakin initially recruits
K1901E and R1914E envoplakin to the cytoskeleton via
heterodimerization, and that subsequently the mutant
envoplakins are less likely to be retained in place, once a
cytoskeletal localization has been achieved, because of their
compromised ability to bind vimentin. Thus the envoplakin–
periplakin–vimentin interaction may be dynamic, facilitating
cytoskeletal reorganization and remodelling during processes
such as wound healing and epidermal differentiation. The in vivo
interactions are complex, with both envoplakin and periplakin
containing linker domains that may also contribute to
intermediate ﬁlament recognition subject to oligomerization,
disulﬁde bond formation and phosphorylation21–26. Thus the
PRD not only binds intermediate ﬁlament proteins but may also
aid in assembly and disassembly of envoplakin–periplakin–
intermediate ﬁlament complexes.
Our model provides a basis for understanding the mechanism
by which plakin proteins containing multiple PRDs, such as
desmoplakin and plectin, bind to intermediate ﬁlaments. That is,
plakin proteins with multiple PRD modules bind to ﬁlaments
such as vimentin which project multiple acidic patches along the
length of their cylindrical surfaces. This would allow the proteins
to engage dynamically at more than one location. Formation of
larger plakin protein networks in cell–cell and cell–matrix
junctions could allow further interactions with intermediate
ﬁlament proteins, thus reinforcing the links. Such multivalent
interactions could be required to confer the strong interactions
required to maintain desmosomal and hemidesmosomal adhesion
in epithelial tissues that are subject to mechanical stress.
Structure-based phylogenetic analysis suggests that functional
differences exist between the different classes of PRD modules.
The PRD-B and PRD-C subtypes generally possess highly basic
binding grooves, and may bind more tightly to intermediate
ﬁlament cytoskeletons than PRD-A and PRD-D subtypes,
which tend to have lower net charges. Interestingly, similar
PRD–linker–PRD modules are present in all three plakin proteins
that are found in cell junctions that normally resist skin blistering
(that is, desmoplakin, BPAG1e and plectin), and the tight
interaction of plectin with intermediate ﬁlaments is mediated by
this module23. Envoplakin contains a linker–PRD-C module and
its binding to vimentin, as judged by SPR, is relatively weak. Thus
it may be that in the case of envoplakin tight binding to the
cytoskeleton (in the absence of a PRD–linker–PRD module)
requires heterodimerization with its partner periplakin.
The PRD mechanism provides a rational basis for manipulat-
ing plakin proteins and their partners including vimentin, desmin
and keratins. The role of envoplakin in corniﬁed envelope
formation and cell adhesion can now be more precisely probed
and the speciﬁc effects of PRD mutations in disease can be
explained. Sequencing of somatic cancers has identiﬁed 18
mutations in envoplakin’s PRD including Y1831F, D1832Y,
D1981N and R1999C27. While the biological consequences have
yet to be established, these substitutions would have structurally
deleterious effects. Other mutations, such as R1876C that has
been found in an upper aerodigestive tract cancer28, would
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directly compromise intermediate ﬁlament binding. An array of
mutations in desmoplakin PRD’s have been mapped and may
contribute to arrhythmogenic right ventricular cardiomyopathy
(ARVC) pathogenesis29. It is now clear that those such as
G2375R30 and R2639Q31,32 would introduce structural
vulnerabilities into PRD folds. The effects of other mutations
on complex formation can now be modelled, thus helping to
translate genome-wide screening and patient data into speciﬁc
molecular consequences.
Methods
Expression and puriﬁcation of proteins. The wild-type human envoplakin
PRD construct was designed based on the sequence conservation of its structural
elements, and DNA encoding the domain (residues Asp1822–Ala2014) was
synthesized by Shinegene Molecular Biotech (Shanghai, China) and cloned into the
expression vector pProEX-HTC (Life Technologies). Envoplakin PRD mutants
were produced by QuikChange Lightning site-directed mutagenesis (Agilent
Technologies). DNA encoding the envoplakin PRD was transformed into
BL21(DE3) cells. Bacterial cultures were incubated at 37 C in either LB media or
M9 minimal media supplemented with 15NH4Cl. The cells were grown until an
OD600 of 0.6 was reached, the temperature was reduced to 18 C and expression
was induced with 1mM isopropyl-b-D-thiogalactopyranoside (IPTG). Cells were
collected by centrifugation after 18 h and resuspended in phosphate-buffered saline
(PBS) with protease inhibitors (Roche). Cells were lysed using an EmulsiFlex-C3
(Avestin) and cell debris were removed by high speed (75,600g) centrifugation. The
clariﬁed supernatant was applied to a HisTrap column (GE Healthcare) that had
been pre-equilibrated with 500mM NaCl, 10mM imidazole, 20mM Hepes, pH 7.5.
The column was washed with 500mM NaCl, 30mM imidazole, 20mM Hepes,
pH 7.5 and His-tagged protein eluted from the column using 500mM NaCl,
250mM imidazole, 20mM Hepes, pH 7.5. Tobacco Etch Virus protease was added
to the protein and the mixture dialysed in 500mM NaCl, 20mM Hepes, pH 7.5.
The protein was applied to a pre-equilibrated HisTrap column to remove the
cleaved His tag and further puriﬁed by size exclusion chromatography using
an S75 column (GE Life Sciences). Fractions containing the PRD protein were
concentrated using Amicon Ultra-15 Centrifugal Filter Concentrators (Millipore).
Full-length human vimentin (residues Met1-Glu466) was synthesized by
ShineGene and cloned into vector pET21aþ (Novagen). The DNA was
transformed into BL21 (DE3) cells and bacterial cultures grown as before. Cells
were collected by centrifugation, resuspended in PBS with protease inhibitors and
lysed. Vimentin was puriﬁed as described33. Brieﬂy, the lysate was centrifuged and
the insoluble fraction resuspended in 20ml Triton X100, 200mM NaCl, 10mM
EDTA, 50mM Tris-Cl, pH 8, homogenized and re-centrifuged three times. The
pellet was resuspended in 10mM EDTA, 50mM Tris-Cl, pH 8, homogenized and
re-centrifuged. After resuspension in 8M urea, 200 mM EDTA, 5mM DTT,
200mM Tris-Cl, pH 8 and incubated overnight at 4 C, the solubilized vimentin
was collected by centrifugation (27,216g for 30min at 4 C) and stored at  80 C.
For NMR experiments urea was removed from the samples by step-wise dialysis
into 4M urea, 5mM DTT, 10mM Tris-Cl, pH 8, followed by 2M urea, 5mM DTT,
10mM Tris-Cl, pH 8 and ﬁnally 10mM Tris-Cl, pH 7.
DNA encoding vimentin rod residues 99–249, cloned into vector pET21aþ ,
were expressed in BL21 (DE3) cells. The vimentinROD protein was soluble and
puriﬁed using nickel afﬁnity and size exclusion chromatography with the His tag
retained for SPR experiments. D112K and D119K mutant vimentinROD proteins
were puriﬁed in a similar fashion. A vimentinROD double mutant (D112K/D119K)
was insoluble and was puriﬁed by the refolding protocol described for full-length
vimentin.
Crystallization. Initial conditions for crystallization of the envoplakin PRD were
identiﬁed using sparse matrix screening. Crystals were grown by sitting-drop
vapour diffusion methods with a 3-ml drop volume, containing 1 ml of protein
sample (at 6.6mgml 1) and 2 ml of reservoir solution. The optimal reservoir
solution consisted of 20% PEG 3350 and 100mM bis Tris-Cl, pH 6.5. The iodine
derivative of envoplakin PRD was prepared by soaking a single crystal in mother
liquor supplemented with an increasing concentration of sodium iodide up to a
maximum concentration of 350mM for 30min.
Data collection and processing. Before data collection, the native and iodine
derivatized envoplakin PRD crysals were soaked in mother liquor incorporating
increasing concentrations of up to 18% ethylene glycol before being ﬂash cooled at
100K under a nitrogen gas stream (Oxford Cryosystems). Diffraction data were
collected using an in-house MicroMax 007HF rotating anode X-ray generator
(Rigaku) with a Saturn CCD detector. The native envoplakin PRD crystal
diffracted X-rays to 1.6 Å resolution and crystallized in the orthorhombic space
group P212121 with unit cell parameters (a¼ 42.4 Å, b¼ 68.8 Å, c¼ 112Å,
a¼b¼ g¼ 90). The iodine-derivatized envoplakin PRD crystal diffracted X-rays
to 2.2 Å resolution and was isomorphous to the native crystal belonging to the
orthorhombic space group P212121 with unit cell parameters (a¼ 42.3 Å,
b¼ 68.5 Å, c¼ 113.7 Å, a¼ b¼ g¼ 90), suggesting that iodide soaking had little
effect on the internal crystal packing and space group. All diffraction data were
integrated, scaled and merged using programs of the XDS suite34. The relevant
data-processing statistics are listed in Table 1.
Structure determination. Since initial attempts for determining phases with
molecular replacement using desmoplakin PRD-C and PRD-B (PDB codes: ILM5
and ILM7, respectively) failed, the structure of envoplakin PRD was solved by the
single-wavelength anomalous diffraction with iodine anomalous signals. In total,
15 iodine sites were located using phenix.hyss and the initial single-wavelength
anomalous diffraction phases were calculated by Phenix.Autosol35. The anomalous
substructure was reﬁned and extended, and phases were estimated using
PHASER36 followed by density improvement in RESOLVE37. Initial models were
built using Phenix.autobuild38. The ﬁnal model was produced after several iterative
rounds of manual re-building in COOT39 and reﬁnement in PHENIX. The ﬁnal
reﬁnement statistics are listed in Table 1. The stereochemical quality of the protein
structure was veriﬁed using the program PROCHECK40. All non-glycine residues
are found in the allowed regions of the Ramachandran plot. The ﬁnal model
contains two molecules (a and b) in the asymmetric unit which is comprised of
residues D1822-A2014. Structure ﬁgures were produced using Pymol (The PyMOL
Molecular Graphics System, Version 1.5.0.4 Schro¨dinger, LLC), with the potential
electrostatic surface of the envoplakin PRD being calculated using DelPhi41. All
structure comparisons were performed using DALI Pairwise42 and programs of the
CCP4 suite43.
NMR assignment of the envoplakin PRD. Multi-dimensional heteronuclear
NMR spectra were recorded at 298 K on a Varian INOVA 600-MHz spectrometer.
The experiments were performed using a triple resonance cryogenically cooled
probe. The amino-acid sequential assignments of the 15N/13C-labelled envoplakin
PRD were obtained by collecting and analysing a set of triple-resonance
experiments, including HNCACB, CBCA(CO)NH, HNCO, C(CO)NH and
H(CCO)NH. Spectra were processed with NMRPipe44 and analysed using CCPN45
and nmrDraw.
NMR analysis of envoplakin PRD–vimentin binding. All samples analysed by
NMR contained 100 mM 15N-labelled wild type and mutant envoplakin PRD
proteins in 20mM Tris-Cl, pH 7 and 1mM DTT. Heteronuclear single quantum
coherence spectra were recorded at 298 K on a Varian INOVA 600-MHz spec-
trometer. The experiments were performed using a triple resonance cryogenically
cooled probe. Binding to vimentin was monitored by following the changes in peak
intensity on addition of unlabelled vimentin to ﬁnal concentrations of 10, 50, 100
and 200mM. NMR chemical shift assignments could be readily transferred between
constructs and states due to the relatively minor chemical shift changes.
SPR analysis of envoplakin PRD–vimentin binding. Envoplakin PRD-vimentin
binding was measured following immobilization of His-tagged vimentinROD on
nickel-coated (SA) chips (GE Life Sciences) using a Biacore 3000 machine (GE Life
Sciences) and standard protocols. Binding of wild type and mutant envoplakin
PRD (0–100 mM) to His-tagged vimentinROD was measured in the presence of
150mM NaCl in 10mM Hepes, 3mM EDTA, 0.005% Surfactant P20, pH 7.4.
Binding of wild-type envoplakin PRD to His-tagged vimentinROD mutants was
measured in a similar fashion. Data was analysed using BIA Evalutation software
(GE Life Sciences).
Modelling the envoplakin PRD–vimentin complex. The interaction between
envoplakin PRD and vimentin was modelled with HADDOCK17. Envoplakin
residues were classiﬁed as active in vimentin binding based on the results of
perturbations of 15N-resolved NMR signals, exposure in the conserved basic
groove, and mutagenesis experiments while ‘passively involved’ residues were
selected automatically. Vimentin residues contacted by the PRD were predicted
from conservation of sequence motifs and negative charge as well as surface
exposure.
To generate representative structural models of the envoplakin PRD–vimentin
complex, molecular docking experiments were repeated with all available vimentin
structures including PDB entries 1GK4 (ref. 46), 1GK6 (ref. 46), 3G1E (ref. 18),
3KLT (ref. 47), 3SWK (ref. 48), 3TRT (ref. 49) and 3UF1 (ref. 14). Residues selected
for use as restraints can be found in Supplementary Table 1, along with the results
of the HADDOCK runs. Notably, the docking procedure was performed with both
monomeric and dimeric forms of vimentin. The representative structures with the
lowest energies were selected for detailed analysis and displayed.
Transfection, western blotting and pull-down assays. DNA encoding human
envoplakin (residues 1542–2014) with a C-terminal Flag tag (DYKDDDDK),
and DNA encoding human periplakin (residues 1588–1756) with a C-terminal
HA tag (YPYDVPDYA), was cloned into expression vector pcDNA3.1( )
(Life Technologies). Mutant envoplakin constructs were produced using the
QuikChange Lightening kit. Constructs were transfected into cultured HeLa cells
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(supplied by Cancer Research UK, London Research Institute) using GeneJammer
transfection reagent (Agilent Technologies). For western blotting transfected cells
were lysed in SDS sample buffer, resolved by SDS–polyacrylamide gel electro-
phoresis and transferred to Hybond-LFP polyvinylidene diﬂuoride membrane.
Blots were probed with anti-Flag (1:3,000; Sigma F7425), anti-HA (1:500; Santa
Cruz sc-805) and anti-actin (1:20,000; Sigma A5441) antibodies, followed by
HRP-conjugated secondary antibodies (1:1,000; Dako P0447/P0448).
Intracellular interactions between plakin proteins were detected in HeLa cells by
pull-down assays. At 48 h following transfection cells were lysed in PBS containing
1% Triton X-100, 2mM phenylmethylsulphonyl ﬂuoride, 10mgml 1 aprotinin
and 10mgml 1 leupeptin. The insoluble material was pelleted by centrifugation at
13,000 r.p.m. for 10min at 4 C and Flag-agarose beads (Sigma) added to the
supernatant. The tubes were mixed by inversion on a rotating wheel for 45min at
4 C, the beads were then washed repeatedly and bound proteins eluted with SDS
sample buffer. Proteins were separated by electrophoresis, blotted onto hybond
membrane and probed with anti-Flag and anti-HA antibodies. Uncropped scans of
blots showing expression of envoplakin and periplakin in lysates, and the results of
pull-down assays are shown in Supplementary Fig. 8.
Immunoﬂuorescence staining. HeLa cells were grown on glass coverslips in
complete media for 24–36 h before transfection with appropriate DNA plasmids
using GeneJammer reagent. At 48 h following transfection cells were ﬁxed for
10min in 2% paraformaldehyde and permeabilized for 2min with 0.1% Triton
X-100. Cells were co-stained with either anti-Flag (1:1,000) or anti-HA (1:1,000)
and either anti-vimentin (1:75; Cell Signaling #3932) or anti-keratin 8 (1:1,000;
Sigma C5301) antibodies, followed by AlexaFluor-conjugated secondary antibodies
(1:1,000; Molecular Probes A-11017/A-11019/A-21069/A-11070). Coverslips were
mounted onto microscope slides using SlowFade Gold antifade reagent (Life
Technologies). Images were taken using Zeiss LSM510 META confocal system with
 63 oil immersion objective (NA 1.4).
AUC. Sedimentation equilibrium experiments were carried out using a Beckman
XL-1 analytical ultracentrifuge (Beckman Coulter, Palo Alto) with an eight-cell
50Ti rotor. Samples were prepared in 100mM NaCl, 20mM sodium phosphate,
pH 7.4 with three protein concentrations between 0.05 and 4mgml 1 being
loaded into double sector cells and centrifuged at 35,000, 37,000 and 39,000 r.p.m.
for 20 h at 20 C. Sedimentation coefﬁcients and molecular masses were
determined using the continuous c(s) analysis method and SEDFIT software50.
Sedimentation velocity experiments were carried out in the Beckman XL-1
centrifuge with a An50Ti rotor using a double sector cell with a 12mm Epon
charcoal-ﬁlled centre piece. Initial checks were performed at 3,000 r.p.m. The
sample (0.5mgml 1 in 100mM NaCl, 20mM sodium phosphate, pH 7.4) was
then centrifuged at 40,000 r.p.m. for 12 h at 20 C.
SAXS. SAXS data were collected at the X33 beamline, EMBL Hamburg outstation
as described51. Scattering patterns were collected at room temperature using
puriﬁed protein at concentrations between 1 and 5.5mgml 1 in 100mM NaCl,
20mM sodium phosphate, pH 7.2. Given that the 5.5mgml 1 data set gave the
highest signal to noise, the other data sets were discarded, and the 5.5mgml 1
data set was subsequently used for the ﬁnal analysis. Background scattering from
buffer alone was automatically subtracted from the protein scattering proﬁles using
the program PRIMUS52. An average of the ﬁnal ab initio model of the envoplakin
PRD was created using the following steps. Using the data range of 0–0.3 Å 1 the
data was analysed by GNOM53 and the Rg and I0 values calculated. The GNOM
output ﬁle was fed into the program DAMMIF54 that generated 10 models. These
models were aligned and compared using the programs DAMSEL and DAMSUP.
The outputs of these programs were fed into DAMAVER55, which created an
averaged model of the original 10 models. Finally, extraneous regions were ﬁltered
by DAMFILT, which gave the ﬁnal model. The data was compared against the
crystal structure using CRYSOL56.
Far ultra-violet circular dichroism spectroscopy. CD spectra were measured on
a JASCO J-1500 spectrometer using a 1-cm path length cuvette and a protein
concentration of 0.7 mM. The scanned wavelength range was 190–260 nm. The
secondary structure content was estimated from the CD spectra using the CDSSTR
algorithm and reference data set 7 on the DichroWeb server15,16.
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